Exelixis
EXEL
#2096
Rank
$7.19 B
Marketcap
$23.73
Share price
-0.54%
Change (1 day)
27.17%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/S ratio for Exelixis (EXEL)

P/S ratio as of March 2024 (TTM): 3.95

According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.95267. At the end of 2023 the company had a P/S ratio of 4.08.

P/S ratio history for Exelixis from 2001 to 2023

PS ratio at the end of each year

Year P/S ratio Change
20234.0826.93%
20223.21-20.32%
20214.03-36.08%
20206.3113.98%
20195.53-19.92%
20186.91-65.24%
201719.9-11.96%
201622.6-34.72%
201534.6207.89%
201411.2-68.88%
201336.1104.02%
201217.7698.31%
20112.22-54.29%
20104.85-7.48%
20095.2416.52%
20084.50-43.54%
20077.97-9.01%
20068.76-15.35%
200510.3-23.26%
200413.538.21%
20039.75-9.02%
200210.7-52.9%
200122.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
4.09 3.53%๐Ÿ‡บ๐Ÿ‡ธ USA
2.69-31.97%๐Ÿ‡บ๐Ÿ‡ธ USA
5.44 37.70%๐Ÿ‡บ๐Ÿ‡ธ USA
2.46-37.87%๐Ÿ‡ซ๐Ÿ‡ท France
5.55 40.43%๐Ÿ‡บ๐Ÿ‡ธ USA
2.39-39.47%๐Ÿ‡บ๐Ÿ‡ธ USA
2.32-41.29%๐Ÿ‡ฌ๐Ÿ‡ง UK
6.39 61.72%๐Ÿ‡บ๐Ÿ‡ธ USA
5.53 39.87%๐Ÿ‡บ๐Ÿ‡ธ USA